Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic Vlado, Jardine Meg J, Neal Bruce, Bompoint Severine, Heerspink Hiddo J L, Charytan David M., Edwards Robert, Agarwal Rajiv, Bakris George, Bull Scott, Cannon Christopher P., Capuano George, Kollaborációs szervezet: CREDENCE Trial Investigators, Takács Róbert, et al
2019

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From th...

Mahaffey Kenneth W., Jardine Meg J., Bompoint Severine, Cannon Christopher P., Neal Bruce, Heerspink Hiddo J.L, Charytan David M., Edwards Robert, Agarwal Rajiv, Bakris George, Bull Scott, Kollaborációs szervezet: REDENCE Study Investigators, Keltai Katalin, Takács Róbert, et al
2019

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt decline...

Heerspink Hiddo J. L., Cherney David, Kollaborációs szerevezet: DAPA-CKD Trial Committees and Investigators, Wittmann I., Vörös P., Dudás M., Tabak G. A., Kirschner R., Letoha Annamária, Balku I., Hermanyi Z., Zakar G., Mezei I., Nagy G. G., Lippai J., Németh A.
2021